// App-Quantinova.ai

e24038 : Neutrophil-to-lymphocyte ratio (NLR) conversion during checkpoint inhibitors therapy as a early prognostic factor.

Researchers

Presenter

  • Jefferson Rios Pimenta

Principal Investigators

  • Tiago Felismino

  • Alexandre Andre B. A. Da Costa

  • Victor Hugo Fonseca Jesus

  • Daniel Vilarim Araujo

  • Jose A. Rinck

Medical Centers

  • A.C. Camargo Cancer Center, Sao Paulo, Brazil

  • A.C. Camargo Cancer Center, Sao Paulo, Brazil

  • A.C. Camargo Cancer Center, Sao Paulo, Brazil

Locations

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Neutrophil lymphocyte ratio

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved